NCT02462603 - Safety and Biomarker Study of PTC-589 in Participants With Parkinson's Disease | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 17, 2016

Primary Completion Date

January 8, 2019

Study Completion Date

January 8, 2019

Conditions

Parkinson's Disease

Interventions

DRUG

PTC-589

PTC-589 is a redox active molecule and will be provided in a 250 mg tablet formulation.

Trial Locations (5)

DZNE Site, Tübingen

Cedar's Sinai, Los Angeles

University of California, San Francisco, San Francisco

Beth Israel Deaconess Medical Center, Boston

University College of London,Dept. of Clinical Neuroscience, London